Literature DB >> 31848584

One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study.

Anna Gundlund1, Jonas Bjerring Olesen1, Jawad H Butt2, Mathias Aagaard Christensen1, Gunnar H Gislason1,3,4, Christian Torp-Pedersen5,6, Lars Køber2, Thomas Kümler7, Emil Loldrup Fosbøl2.   

Abstract

AIMS: Thromboprophylaxis guidelines for patients with concurrent atrial fibrillation (AF) during infections are unclear and not supported by data. We compared 1-year outcomes in patients with infection-related AF and infection without AF. METHODS AND
RESULTS: By crosslinking Danish nationwide registry data, AF naïve patients admitted with infection (1996-2016) were identified. Those with AF during the infection (infection-related AF) were matched 1:3 according to age, sex, type of infection, and year with patients with infection without AF. Outcomes (AF, thromboembolic events) were assessed by multivariable Cox regression. The study population comprised 30 307 patients with infection-related AF and 90 912 patients with infection without AF [median age 79 years (interquartile range 71-86), 47.6% males in both groups]. The 1-year absolute risk of AF and thromboembolic events were 36.4% and 7.6%, respectively (infection-related AF) and 1.9% and 4.4%, respectively (infection without AF). In the multivariable analyses, infection-related AF was associated with an increased long-term risk of AF and thromboembolic events compared with infection without AF: hazard ratio (HR) 25.98, 95% confidence interval (CI) 24.64-27.39 for AF and HR 2.10, 95% CI 1.98-2.22 for thromboembolic events. Further, differences in risks existed across different subtypes of infections.
CONCLUSION: During the first year after discharge, 36% of patients with infection-related AF had a new hospital contact with AF. Infection-related AF was associated with increased risk of thromboembolic events compared with infection without AF and our results suggest that AF related to infection may merit treatment and follow-up similar to that of AF not related to infection. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Infection; Recurrence; Secondary atrial fibrillation; Stroke; Thromboembolism

Mesh:

Substances:

Year:  2020        PMID: 31848584     DOI: 10.1093/eurheartj/ehz873

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

Review 1.  Prevalence of New-Onset Atrial Fibrillation and Associated Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis.

Authors:  Bernadette Corica; Giulio Francesco Romiti; Stefania Basili; Marco Proietti
Journal:  J Pers Med       Date:  2022-03-30

2.  Self-monitoring for recurrence of secondary atrial fibrillation following non-cardiac surgery or acute illness: A pilot study.

Authors:  Nicole Lowres; Graham S Hillis; Marc A Gladman; Mark Kol; Jim Rogers; Vincent Chow; Ferris Touma; Cara Barnes; Joanne Auston; Ben Freedman
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-29

3.  Thromboembolic Risk in Patients With Pneumonia and New-Onset Atrial Fibrillation Not Receiving Anticoagulation Therapy.

Authors:  Mette Søgaard; Flemming Skjøth; Peter B Nielsen; Jesper Smit; Michael Dalager-Pedersen; Torben B Larsen; Gregory Y H Lip
Journal:  JAMA Netw Open       Date:  2022-05-02

4.  Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry.

Authors:  Aitor Uribarri; Iván J Núñez-Gil; Álvaro Aparisi; Ramón Arroyo-Espliguero; Charbel Maroun Eid; Rodolfo Romero; Víctor M Becerra-Muñoz; Gisela Feltes; María Molina; Marcos García-Aguado; Enrico Cerrato; Thamar Capel-Astrua; Emilio Alfonso-Rodríguez; Alex F Castro-Mejía; Sergio Raposeiras-Roubín; Carolina Espejo; Nerea Pérez-Solé; Alfredo Bardají; Francisco Marín; Óscar Fabregat-Andrés; Fabrizio D'ascenzo; Francesco Santoro; Ibrahim Akin; Vicente Estrada; Antonio Fernández-Ortiz; Carlos Macaya
Journal:  Rev Esp Cardiol (Engl Ed)       Date:  2021-01-13

5.  [Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry].

Authors:  Aitor Uribarri; Iván J Núñez-Gil; Álvaro Aparisi; Ramón Arroyo-Espliguero; Charbel Maroun Eid; Rodolfo Romero; Víctor M Becerra-Muñoz; Gisela Feltes; María Molina; Marcos García-Aguado; Enrico Cerrato; Thamar Capel-Astrua; Emilio Alfonso-Rodríguez; Alex F Castro-Mejía; Sergio Raposeiras-Roubín; Carolina Espejo; Nerea Pérez-Solé; Alfredo Bardají; Francisco Marín; Óscar Fabregat-Andrés; Fabrizio D'ascenzo; Francesco Santoro; Ibrahim Akin; Vicente Estrada; Antonio Fernández-Ortiz; Carlos Macaya
Journal:  Rev Esp Cardiol       Date:  2021-03-02       Impact factor: 4.753

6.  Very Low Prevalence and Incidence of Atrial Fibrillation among Bolivian Forager-Farmers.

Authors:  Christopher J Rowan; Michael A Eskander; Edmond Seabright; Daniel Eid Rodriguez; Edhitt Cortez Linares; Raul Quispe Gutierrez; Juan Copajira Adrian; Daniel Cummings; Bret Beheim; Kirsten Tolstrup; Abinash Achrekar; Thomas Kraft; David E Michalik; Michael I Miyamoto; Adel H Allam; L Samuel Wann; Jagat Narula; Benjamin C Trumble; Jonathan Stieglitz; Randall C Thompson; Gregory S Thomas; Hillard S Kaplan; Michael D Gurven
Journal:  Ann Glob Health       Date:  2021-02-16       Impact factor: 2.462

Review 7.  Sepsis-driven atrial fibrillation and ischaemic stroke. Is there enough evidence to recommend anticoagulation?

Authors:  Isuru Induruwa; Eleanor Hennebry; James Hennebry; Mrinal Thakur; Elizabeth A Warburton; Kayvan Khadjooi
Journal:  Eur J Intern Med       Date:  2021-11-09       Impact factor: 4.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.